NTLA

#4317
Intellia Therapeutics, Inc. - Common Stock
0.1 4 USD
-98.97%
Sector: Atención Sanitaria
Básica: USD
Divisa de beneficio: USD
Rango diario
0.14
0.14
Rango anual
0.12
17.09
Cambio diario
-98.97%
Variación mensual
-98.89%
Variación en los últimos 6 meses
-98.40%
Cambio anual
-98.97%
Cierres anteriores
13.6 8
Open
0.1 4
Mínimo
0.1 4
High
0.1 4
Volumen
154
Ver el calendario completo Full chart

Financials

Visión general Informes Estadísticas
Trimestre Año
  • Market Capitalization 19.66 M
  • Employee 377
  • Founded 2014
  • CEO John Leonard
  • Website www.intelliatx.com
  • Headquarter Delaware, United States
  • FIGI BBG007KC7PB0
  • Industry Biotecnología
Ingresos totales
Beneficio neto
Beneficio básico por acción
Deuda total
Flujo de caja libre
Efectivo y equivalentes
Ratio precio/beneficio
-2.36
Relación precio/flujo de caja
14.4

Intellia Therapeutics, Inc. - Common Stock

Intellia Therapeutics, Inc. is an American clinical-stage biotechnology company focused on developing novel, potentially curative therapeutics leveraging CRISPR-based technologies. The company's in vivo programs use intravenously administered CRISPR as the therapy, in which the company's proprietary delivery technology enables highly precise editing of disease-causing genes directly within specific target tissues. Intellia's ex vivo programs use CRISPR to create the therapy by using engineered human cells to treat cancer and autoimmune diseases. The CRISPR gene editing system was originally invented by Jennifer Doudna, one of Intellia's scientific founders, and Virginijus Šikšnys. The company has entered into a number of different research and development collaborations with leading and emerging biotechnology companies including Novartis, Regeneron, Avencell, SparingVision, Kyverna, and ONK Therapeutics. Intellia has two in vivo programs in ongoing clinical trials. NTLA-2001 is an investigational CRISPR therapy candidate for the treatment for ATTR amyloidosis currently in Phase 1 studies.

Noticias